A severe complication of pelvic inflammatory diseases both in women and in men is adhesion. It may be treated using a hyaluronidase [stabilized] enzyme product.
Pelvic diseases present a large-scale and complex medical issue. First, because of the oligosymptomatic character of the course of today’s infectious diseases. If initially the symptoms of prostatitis or inflammatory women’s reproductive organ disorders do not disturb the regular life, there is a high risk that such patient will consult the doctor only when it is time to receive treatment for infertility, inappropriate urination, or other complications. Second, because patients are reluctant to seek medical advice. Seeking medical attention too late results in pelvic disease treatment at the stage when inflammation develops into adhesion. The scar tissue does not readily respond to treatment.
Longidaze (a stabilized hyaluronidase enzyme) used concomitantly with other pharmaceuticals prevents progressive fibrosis, i.e. the formation of adhesions and fibrosis focal areas, reduces inflammation, and increases elasticity of the already formed adhesions. The product has proved its efficacy in treatment of pelvic inflammatory diseases both in men and women.
Most often, prostatitis develops into a chronic disease presenting with non-intense pain, and a sense of discomfort in the perineum radiating to the sacrum, reproductive organs, or rectum. Frequent, painful, sometimes inappropriate urination is periodically observed. Most men ignore these symptoms until prostatitis and associated complications start seriously affecting their quality of life.
A consequence of a long-standing prostatitis may be bacterial process distribution in the urinary system, which leads first to bladder and then to kidney inflammation. Seminal vesiculitis, orchitis, epididymitis, and sperm quality deterioration may ultimately result in men’s infertility. Besides, inflammatory processes in the prostate gland may be a cause of prostate adenoma or cancer. Chronic prostatitis induces erectile dysfunction because of local nerve involvement in the in the inflammatory process..
For more than 10 years, in the Russian clinical practice, Longidaze (a combined product by NPO Petrovax Pharm, LLC) has been successfully used to prevent and treat fibrosis of different localizations. This is a combination of hyaluronidase with a high molecular weight vehicle. Longidaze therapeutic effect is superior to that of similar enzyme products due to enzyme stabilization as well as the presence of other pharmacological properties contributed by the biologically active vehicle (anti-inflammatory, and chelating agent).
Based on the data of the clinical study (2004–2005) conducted at the Urology Clinic of A.I. Evdokimov Moscow State University of Medicine and Dentistry (Russian Ministry of Health), the mean treatment efficacy in the chronic prostatitis patient group receiving Longidaze was 82.1% vs. 54.8% in the reference group. Longidaze use concomitantly with the standard treatment promotes disease disappearance or reduction, and reduces chronic prostatitis recurrence frequency.
In Russia, in more than 50% of women visiting women's health clinics, pelvic inflammatory diseases are diagnosed on an annual basis. Pelvic inflammatory diseases are of infectious origin. Acute onset of a disease is generally preceded by vagina and cervix colonization by opportunistic bacteria. In most cases, natural protection mechanisms can prevent infection progression. However, given the initiating agent effect, the bacteria invade the uterine cavity, and fallopian tube opening. In this respect, especially dangerous are post-labor, post-abortion, and menstruation periods as well as various intrauterine manipulations. As a result, endometritis, salpingitis, ovaritis, myometritis, or pelvioperitonitis may develop. An outcome of any such inflammation may be adhesion, and uterine synechiae (adhesions). The quality of life of such patients deteriorates appreciably because of chronic pelvic pain, and menstrual dysfunction. Infertility may cause a divorce and depression.
One of major infertility causes is pelvic adhesions leading to tubal and peritoneal infertility forms. These are diagnosed, on average, in 50% of all patients seeking medical advice for infertility.
Another risk factor is pelvic and abdominal cavity surgeries. Even if a surgery was performed not because of an infectious process, inflammation develops in the abdominal cavity as a result of surgical trauma, or peritoneum injury caused by drying or exposure to cold during the surgical intervention. Fibrin build-up in case of blood entry into the abdominal cavity triggers off the connective tissue adhesion mechanism.
Hyaluronidase is an agent that produces an effect on the damaged connective tissue, and does not cause adverse reactions. Under its effect, the connective tissue matrix loses its viscosity, and, as a result, tissue barrier permeability as well as scar tissue elasticity increase.
Longidaze does not damage the normal connective tissue while causing structural changes in the changed (both in terms of composition and structure) pathological scar tissue. Longidaze is safe because it is not embryotoxic, and does not produce either a mutagenic or carcinogenic effect. Longidaze spectrum is much broader than that of other enzyme products as it not only affects the connective tissue structure but also inhibits its causative factor, i.e. an inflammatory process.
Longidaze prevents the formation of new adhesions in exacerbation of the inflammation, makes the existing adhesions more elastic, reduces inflamed tissue edema, and improves the interstitial fluid flow, which increases antibacterial therapy efficacy. Longidaze inclusion in combined treatment of acute and chronic pelvic inflammatory diseases as well as post-surgery therapy of abdominal cavity organs provides for enhancing treatment efficacy, and preventing adhesion formation, or reducing the intensity of the ongoing adhesion process.